scholarly journals A case report: pseudoxanthoma elasticum diagnosed based on ocular angioid streaks and the curative effect of Conbercept treatment

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Chaoxiong Cui ◽  
Zhanyu Zhou ◽  
Yi Zhang ◽  
Ding Sun
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Intravitreal Injection ◽  
Visual Function ◽  
Past History ◽  
Paraffin Section ◽  
Pseudoxanthoma Elasticum ◽  
Angioid Streaks ◽  
Corrected Visual Acuity ◽  
Best Corrected Visual Acuity

Abstract Background This article is a case report of pseudoxanthoma elasticum (PXE) which was diagnosed based on significant angioid streaks (AS) with choroidal neovascularization (CNV) and regain normal visual function by intravitreal injection with Conbercept. Case presentation A 51-year-old woman was referred to the Ophthalmology Department of Qingdao Municipal Hospital (Qingdao, China) on September 14, 2020 for metamorphopsia and loss of vision in the left eye in the preceding three days. Past history: high myopia for more than 30 years, best corrected visual acuity (BCVA) of both eyes was 1.0 (5 m Standard Logarithm Visual Acuity chart in decimal notations), hypertension for six years, and cerebral infarction two years ago, no history of ocular trauma or surgeries or similar patients in family was documented. We used methods for observation, including fundus examination, optical coherence tomography (OCT), fluorescein angiography combined with indocyanine green angiography (FFA + ICGA). Due to her symptoms and manifestations, along with the appearance of her neck skin, which resembled ‘chicken skin’, we speculated that she should be further examined at the Department of Dermatology by tissue paraffin section and molecular pathology analyses, and the diagnosis of PXE was then confirmed. After intravitreal injection with Conbercept (10 mg/ml, 0.2 ml, Chengdu Kanghong Biotechnologies Co., Ltd.; Chengdu, Sichuan, China) she regained her BCVA. Conclusions This patient regained her best corrected visual acuity through intravitreal injection with Conbercept. To the best of our knowledge, no publications are available on cases in which a vision loss and the normal visual function can be reverted by intravitreal injection with Conbercept. Although PXE is a disease with low incidence and thus no effective cure established, targeted symptomatic treatment can effectively retard the disease progression and improve visual function, such as intravitreal injection with Conbercept.

scholarly journals Rapid progression of chorioretinal atrophy in punctate inner choroiditis: a case report

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
Yuka Kasuya ◽  
Yuji Inoue ◽  
Satoru Inoda ◽  
Yusuke Arai ◽  
Hidenori Takahashi ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Epiretinal Membrane ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Japanese Woman ◽  
Rapid Progression ◽  
Chorioretinal Atrophy ◽  
Corrected Visual Acuity ◽  
Best Corrected Visual Acuity

Abstract Background The chorioretinal inflammatory lesions occurring in punctate inner choroiditis evolve into punched-out atrophic scars. Typically, the progression is gradual. We report a case of highly myopic punctate inner choroiditis with rapid progression of chorioretinal atrophy. Case presentation A 48-year-old Japanese woman with high myopia presented with decreased visual acuity. Best-corrected visual acuity was 20/28 in the right eye and 20/16 in the left eye; axial length was 29.0 mm and 28.7 mm, respectively. Fundoscopy revealed an epiretinal membrane in the left eye. Three years later, the best-corrected visual acuity in the left eye had decreased to 20/33; at this time, the patient underwent vitrectomy with epiretinal membrane and internal limiting membrane peeling in this eye. Six months later, the best-corrected visual acuity in the left eye decreased suddenly to 20/100. Optical coherence tomography showed a nodule-like lesion in the outer retina with disruption of the retinal pigment epithelium and a focally thickened choroid, compatible with PIC. One month later, the choroidal thickness had decreased. The central chorioretinal atrophy expanded rapidly at a rate of 0.45 mm2/year over the next 3 years, and new areas of patchy focal chorioretinal atrophy developed in the perifovea. Conclusions Rapid progression of chorioretinal atrophy was observed in a patient with punctate inner choroiditis. Because punctate inner choroiditis is often associated with degenerative myopia, the retina is fragile and may be susceptible to mechanical damage. This case report alerts clinicians to the need for careful management of patients with punctate inner choroiditis, especially after vitrectomy.

scholarly journals Self-Reported Visual Function Index (VF-14) and Its Correlation with Best Corrected Visual Acuity in Elderly

2017 ◽  
Vol 15 (02) ◽  
pp. 199-205
Author(s):  
SITI ZAWIYAH MANSOR ◽  
SAADAH MOHAMED AKHIR ◽  
ZAINORA MOHAMMED ◽  
BARIAH MOHD ALI ◽  
NORHANI MOHIDIN
Keyword(s):  
Visual Acuity ◽  
Visual Function ◽  
Corrected Visual Acuity ◽  
Function Index ◽  
Best Corrected Visual Acuity

Subthreshold micropulse yellow (577nm) laser versus intravitreal Ranibizumab in treatment of center involving diabetic macular oedema

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Esraa Abdelhakeem Diab ◽  
Alaa Fathy Mahmoud ◽  
Mohamed Abd el-hakim Zaki ◽  
Ahmed Abdel-aleem Mohmaed ◽  
Mohamed Hanafy Abdel-aziz
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
P Value ◽  
Micropulse Laser ◽  
Corrected Visual Acuity ◽  
Subthreshold Micropulse Laser ◽  
Group B ◽  
Best Corrected Visual Acuity

Abstract Purpose To evaluate the effectiveness of subthreshold micropulse laser as compared to intravitreal injection of ranibizumab in treatment of center involving diabetic macular oedema. Methods A total of 76 eyes of 62 patients with center involving diabetic macular oedema were divided into two groups. Group A received intravitreal injection of ranibizumab while group B received subthreshold micropulse laser with rescue intravitreal injection of ranibizumab. The change from baseline in best correscted visual acuity and central subfield thickness were compared at 3, 6, 9 and 12 months follow-up. Any adverse effects were recorded. Results Group A (n = 34 eyes) experienced a statistically significant improvement in best corrected visual acuity (from 0.32±0.16 Log MAR at baseline to 0.21±0.14 Log MAR at 12 months) (P value =0.006), with a statistically significant reduction in central subfield ghickness (from 352.06±34.34µm to 289.47±58.88 µm) (P value=0.001). Group B (n = 42 eyes), also experienced a statistically significant improvement in best corrected visual acuity (from 0.34±0.22 Log MAR at baseline to 0.13±0.31 Log MAR at 12 months) (P value=0.001), with a statistically significant reduction in central subfield thickness (from 300±47.34µm to 253.12±39.60 µm at 12 months) (P value= 0.009). The mean difference in best corrected visual acuity between the group B and group A was -0.08 Log MAR with a 95% CI ranging from -0.197 to 0.037, which supports the claim of non-inferiority between the two treatment regimens. No adverse effects from subthreshold micropulse laser were recorded in both groups. Conclusion subthreshold micropulse laser with rescue intravitreal injection of ranibizumab was non inferior to intravitreal injection of ranibizumab in treatment of center involving diabetic macular oedema as regards the mean change in best corrected visual acuity.

scholarly journals Bevacizumab for Macular Serous Neuroretinal Detachment in Tilted Disk Syndrome

2010 ◽  
Vol 2010 ◽  
pp. 1-3 ◽  
Author(s):  
Paolo Milani ◽  
Alfredo Pece ◽  
Luisa Pierro ◽  
Patrizio Seidenari ◽  
Paolo Radice ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Pigment Epithelium ◽  
Retinal Pigment ◽  
Monthly Interval ◽  
Serous Macular Detachment ◽  
Corrected Visual Acuity ◽  
Total Observation ◽  
Tilted Disk ◽  
Best Corrected Visual Acuity

Background. Tilted disc syndrome (TDS) is a congenital anomaly characterized by “tilting” of the optic disc tipycally associated with myopic astigmatism, visual field defect, inferior staphyloma, and retinal pigment epithelium atrophy. Associated complications such as macular serous neuroretinal detachment are well described; however, ideal therapy for such complication is unknown.Methods. One interventional case report is hereby described. A patient affected by macular serous neuroretinal detachment-complicated tilted disk syndrome underwent a complete ophthalmic examination. Optical coherence tomography and fluorescein angiography were taken at baseline and at scheduled visits. Two intravitreal treatments of bevacizumab (avastin, 1.25 mg/0.05 mL) were performed at monthly interval.Results. At scheduled visit, one month after the second injection, OCT depicted persistence of neuroretinal detachment. Best-corrected visual acuity remain stable as well as metamorphopsia and functional discomfort.Conclusion. Clinical evidence of this brief interventional case report indicates that one patient affected by recent serous macular detachment-complicated TDS did not benefit from 2 consecutive monthly intravitreal Avastin treatments. Best-corrected visual acuity remained stable over a total observation period of 6 months.

Intravitreal aflibercept for management of choroidal neovascularization secondary to angioid streaks

2020 ◽  
pp. 112067212092830
Author(s):  
Maurizio Battaglia Parodi ◽  
Maria Vittoria Cicinelli ◽  
Alessandro Marchese ◽  
Chiara Giuffrè ◽  
Francesco Viola ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Adverse Events ◽  
Choroidal Neovascularization ◽  
Central Macular Thickness ◽  
Angioid Streaks ◽  
Serious Adverse Events ◽  
Corrected Visual Acuity ◽  
Intravitreal Aflibercept ◽  
Best Corrected Visual Acuity

Purpose To investigate the effect and the safety of intravitreal aflibercept in patients affected by choroidal neovascularization secondary to angioid streaks with a long-term follow-up. Methods Multicentre, open-label, phase IIb study (EYLEA-STRIE, EudraCT Number 2014-000986-30) involving four Italian centres (IRCCS Ospedale San Raffaele (Milano), Fondazione G.B. Bietti (Roma), Policlinico (Milano), Ospedale Luigi Sacco (Milano)). Patients with active choroidal neovascularization secondary to angioid streaks with foveal involvement were prospectively enrolled and followed for 18 months. All the patients received intravitreal 2 mg/0.05 mL aflibercept at the time of enrolment, followed by a pro-re-nata regimen for 48 weeks. Best-corrected visual acuity and central macular thickness were measured monthly. Adverse events were monitored at each visit. Results Twenty-three eyes of 20 patients were analysed. Mean number of injections per patient was 4.30 ± 1.2. At week 48, the best-corrected visual acuity was 0.42 ± 0.40 LogMAR (p = 0.6 from baseline) and 18 eyes (81.8%) featured stability within 15 letters. The central macular thickness significantly reduced (p = 0.03). Eleven ocular non-serious adverse events and two serious adverse events were observed (one case of endophthalmitis and one case of acute gastritis were reported). Conclusion Intravitreal aflibercept represents a valid option for the management of choroidal neovascularization complicating angioid streaks. Further studies with longer follow-up and different therapeutic regimens are warranted to ascertain the best control of the disease.

scholarly journals Αγγειοειδείς ταινίες

2006 ◽  
Author(s):  
Ηλίας Γεωργαλάς
Keyword(s):  
Visual Acuity ◽  
Photodynamic Therapy ◽  
Laser Photocoagulation ◽  
Age Related Macular Degeneration ◽  
Fundus Photography ◽  
Angioid Streaks ◽  
Corrected Visual Acuity ◽  
Best Corrected Visual Acuity ◽  
Group 1

Angioid streaks are irregular crack like dehiscences in Bruch's membrane that invariably radiate outward from the peripapillary area in all directions9. They are associated with a wide variety of systemic diseases, such as pseudoxanthoma elasticum, Ehler-Danlos syndrome, Paget's disease and sickle-cell hemoglobinopathies9.The prognosis in patients with angioid streaks is guarded because visual impairment occurs in 70% to 86% due to the occurrence of macular choroidal neovascularization (CNV)9,15,51. The natural history of such lesions is poor, with most resulting in fovea involvement and central vision loss9,187. Laser photocoagulation treatment of CNV may be beneficial in selected cases169,171,189,191. However, the recurrence rate is higher than with CNV associated with other macular disorders168,170 and the final results reported in the literature as being rather disappointing9. Recently, limited macular translocation176,177, as well as photodynamic therapy with verteporfin (PDT)151,152,154,155,157,182 were searched as alternative treatment modalities for subfoveal CNV due to angioid streaks in small series of patients with controversial results.The purpose of this study is to evaluate the effectiveness of conventional PDT with verteporfin in a large series of patients with subfoveal or juxtafoveal CNV due to angioid streaks and to compare it to the effectiveness of early retreatment PDT (8 weeks following initial therapy) in patients who experienced disease progression.MATERIALS AND METHODSA prospective analysis of 36 eyes of 33 consecutive patients with subfoveal or juxtafoveal CNV secondary to angioid streaks that were treated with PDT from January 2001 through January 2005 and completed at least 18 months of the follow-up time, was conducted. The greatest linear dimension of the entire lesion had to be 6000 pm or less. Eyes with best corrected visual acuity of less than 20/400 were not treated. None of the eyes had been previously treated by conventional laser photocoagulation for the macular CNV.Prior to the treatment, each patient had undergone a complete ocular examination including contact lens fundus biomicroscopy, color or red-free fundus photography, and digital fluorescein angiography (FA) using the Topcon Imagenet 2000 Digital Imaging System with TRC-50IA fundus camera (Topcon Corporation, Paramus, New Jersey, USA). Fluorescein angiograms were evaluated for lesion size and leakage of the neovascular membrane. Best-corrected visual acuity was determined in all patients using standard Snellen charts.Patients were divided in 2 groups. In group 1, retreatments were performed according to the standard protocol followed in the Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Investigation (TAP) every 12 weeks107, 146. During this time, 17 eyes of 15 patients were included in the study in Group 1. In Group 2, 19 eyes of 17 patients received early retreatments (8 weeks after the previous PDT) when indicated according to the criteria of the TAP study for conventional 3-month retreatment.The follow-up time of the patients ranged from 18 to 66 months (mean 37.6 months). The re-examinations followed the same procedure as the first examination. Informed consent for examination and treatment was obtained from each patient after a full explanation of the procedure.Numerical data in the text and the tables are presented as mean (±SD). Improvement or decline of visual acuity was defined as a change of at least two lines.

scholarly journals LETTER TO THE EDITOR Excision of Congenital Bilateral Persistent Pupillary Membrane in a Child with Exotropia

2015 ◽  
Vol 9 (1) ◽  
pp. 33-35
Author(s):  
Michiko Iida ◽  
Tatsuya Mimura ◽  
Mari Goto ◽  
Yuko Kamei ◽  
Aki Kondo ◽  
...  
Keyword(s):  
Visual Acuity ◽  
Case Report ◽  
Surgical Treatment ◽  
Histopathological Examination ◽  
Crystalline Lens ◽  
Ocular Tissues ◽  
Corrected Visual Acuity ◽  
The Right ◽  
Best Corrected Visual Acuity ◽  
High Hyperopia

Purpose : To report the clinical and histopathological findings of a patient who had bilateral persistent pupillary membrane with exotropia and high hyperopia. Methods : Case Report: A 7-year-old boy presented with a persistent pupillary membrane in both eyes. His best corrected visual acuity (BCVA) was 20/20 in the right eye and 20/32 in the left eye with exotropia of 18 prism diopters. He underwent surgical resection of both membranes. At 5 months postoperatively, BCVA was 20/20 with final bilateral refraction of +6.5 D in both eyes. Exotropia and photophobia showed improvement immediately after surgery. Histopathological examination revealed typical features of normal iris tissue in the excised membranes. Conclusion : Bilateral persistent pupillary membranes were excised successfully without injury to other ocular tissues, including the crystalline lens. Surgical treatment may be required for the management of persistent pupillary membrane associated with visual impairment such as exotropia or photophobia.

scholarly journals Efficacy and Safety of Intravitreal Injection Ranibizumab versus Triamcinolone Acetonide in Diabetic Macular Oedema - A Prospective Randomized Study, Gorakhpur, Uttar Pradesh

2021 ◽  
Vol 8 (27) ◽  
pp. 2444-2450
Author(s):  
Ramyash Singh Yadav ◽  
Ram Kumar Jaiswal ◽  
Punita Tripathi ◽  
Mridula Ranjan ◽  
Chiranji Rai
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Triamcinolone Acetonide ◽  
Macular Oedema ◽  
Diabetic Macular Oedema ◽  
Foveal Thickness ◽  
Corrected Visual Acuity ◽  
Group A ◽  
Group B ◽  
Best Corrected Visual Acuity

BACKGROUND Diabetic macular oedema is a sight threatening complication of diabetic retinopathy. Vascular endothelial growth factor (VEGF) plays an important role in developing diabetic macular oedema. There are many treatment options available for diabetic macular oedema such as laser therapy, intravitreal injectable medications like anti-VEGF and steroids. This study intends to compare the efficacy and safety of intravitreal injection Ranibizumab (anti-VEGF) and Triamcinolone acetonide (steroid) in diabetic macular oedema. METHODS This is a prospective randomized study conducted among 42 patients ≥ 18 years of age with diabetic macular oedema presenting to outpatient department in a tertiary care centre in Gorakhpur, UP, conducted from November 2019 – December 2020. 42 participating patients were divided into 2 groups, A and B with 21 patients in each group. Group A treated with intravitreal injection Ranibizumab (0.05 ml ; 0.50 mg) and group B treated with intravitreal injection Triamcinolone acetonide (4 mg in 0.1 ml). All patients were followed-up at 2 week and 4 week after injection for best corrected visual acuity, intraocular pressure, foveal and para-foveal thickness. Optical coherence tomography was performed for measuring foveal and para-foveal thickness. RESULTS The mean age group being 56.48 years in group A and 58.63 years in group B with 12 male and 9 female patients in group A and 10 male and 11 female patients in group B with no dropout during study period. Both injections were equally effective in reducing foveal and para-foveal thickness and improving best corrected visual acuity. Intraocular pressure (IOP) was stable in Ranibizumab treated group but Triamcinolone treated group showed raised IOP in few patients, required anti-glaucoma medications. CONCLUSIONS Both treatment types had good efficacy in reducing foveal and para-foveal thickness and thus improving best corrected visual acuity, but intravitreal Ranibizumab is safer and well tolerated along with good efficacy in patients with diabetic macular oedema. KEYWORDS Best Corrected Visual Acuity, Diabetic Macular Oedema, Foveal and Para-Foveal Thickness, Intravitreal Ranibizumab, Intravitreal Triamcinolone Acetonide

scholarly journals Macular Hole Progression following Ocriplasmin Intravitreal Injection

2014 ◽  
Vol 2014 ◽  
pp. 1-2 ◽  
Author(s):  
Edward Casswell ◽  
Guillermo Fernandez-Sanz ◽  
Danny Mitry ◽  
Sheila Luk ◽  
Rahila Zakir
Keyword(s):  
Optical Coherence Tomography ◽  
Visual Acuity ◽  
Intravitreal Injection ◽  
Macular Hole ◽  
Optical Coherence ◽  
Vitreomacular Adhesion ◽  
Blurred Vision ◽  
Corrected Visual Acuity ◽  
Best Corrected Visual Acuity

Ocriplasmin is a protease which has been approved for the treatment of symptomatic vitreomacular adhesion (VMA). A 63-year-old presented with blurred vision in the left eye and a best corrected visual acuity of 6/18. Optical coherence tomography revealed VMA with an underlying macular hole and she subsequently underwent a left intravitreal ocriplasmin injection. One week after the injection, VMA had been released but with enlargement of the macular hole and a drop in her BCVA to 6/60. This persisted at 1 month after the injection. It is important to warn patients that ocriplasmin may lead to an enlargement of their macular hole with resultant loss in visual acuity.

Sign in / Sign up

Export Citation Format

Share Document